The trial (NCT06207370) evaluates tafenoquine combined with standard treatment for babesiosis, addressing a critical unmet medical need.The clinical site is...
Presentation to Feature Lead Drug Candidate GT-02287 and Magellan Drug Discovery PlatformBETHESDA, Md., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Gain...
The overview presentation will review some of the Company’s recent achievements as well as the outlook for upcoming data milestonesJERUSALEM,...
Ness-Ziona, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...
Twice daily (BID) dosing regimen expected to maximize clinical benefit for patients by optimizing the activity of Aprea’s experimental drug,...
ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will...
Media Release Event to be held virtually via live webcast and archived on www.genmab.com Copenhagen, Denmark; December 11, 2024 –...
TOKYO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (the “Company” or “MEDIROM”) announces that two...
JEDDAH, Saudi Arabia, Dec. 11, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) in Jeddah successfully...
- Financing led by Bain Capital Life Sciences with significant participation from existing and new investors - Proceeds will support...
EDISON, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (Nasdaq: HEPA) (the “Company” or “Hepion”), a clinical stage...
Citizen Petition seeks correction of expiration date for New Chemical Entity (NCE) exclusivity on VOQUEZNA (vonoprazan) tablets Orange Book listingsPhathom...
Presentations complement topline data with new data from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive...
Teva to provide two generic inhaler products to Direct Relief for its network of free and charitable clinicsThe program, launching...
MINNEAPOLIS, MN, Dec. 11, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company” or “FOXO”) announces a series of restructuring...
TIGeR-PaC is Evaluating the TAMP™ (Trans-Arterial Micro-Perfusion) Therapy Platform for the Treatment of Locally Advanced Pancreatic Cancer Dr. Meredith Pelster,...
The Company will review on Thursday, December 12th, at 12:00 p.m. EST. GARDEN CITY, NY, Dec. 11, 2024 (GLOBE NEWSWIRE)...
– Findings published in Brain Sciences showed missed doses and potential for injury when waking to take a second dose...
Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6...
The ongoing obesity Phase 2 trial is a randomized, double-blind, placebo-controlled, dose finding, clinical trial to evaluate the safety and...